Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study

Phase 3positiveIvonescimabPositive

AI Analysis

Summary

Summit Therapeutics announced updated overall survival results from the global Phase III HARMONi trial of ivonescimab plus chemotherapy, showing consistent favorable efficacy in both Western and Asian patient populations.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Updated overall survival analysis showed consistent, favorable results in Western and Asian patients

Importance:7/10

Sentiment:

0.75

oncologyphase_3_dataoverall_survivalglobal_trialcombination_therapy

Related Companies

$SMMT

Read the original article

Published by Drugs.com Clinical Trial Results on July 22, 2026 12:08 AM

Read Original